Medicines Discovery Catapult (MDC) and Crown Bioscience have formed a strategic global collaboration to support companies across the radiopharmaceutical pipeline.
The two are creating a platform for companies to evaluate their radiopharmaceutical therapies. The platform aims to improve testing of how radiopharmaceuticals work, how the body responds to them, and how effective they are.
MDC and Crown Bioscience will also deliver preclinical comparator studies with approved standards of care to support preparation of successful investigational new drug submissions.
The two companies added that this collaboration will provide a fully integrated preclinical workflow for companies developing radiotherapeutics to accelerate drug development.
